Multicentre randomised phase II trial of gemcitabine + platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2

European Journal of Cancer

Volumn 51, Issue 1, 2015, Pages 45-54

  Oudard, Stéphane ^a   Culine, Stéphane ^b   Vano, Yann ^a   Goldwasser, François ^c   Théodore, Christine ^d   Nguyen, Thierry ^e   Voog, Eric ^f   Banu, Eugeniu ^a   Vieillefond, Annick ^c   Priou, Franck ^g   Deplanque, Gaël ^h   Gravis, Gwenaëlle ⁱ   Ravaud, Alain ^j   Vannetzel, Jean Michel ^k   Machiels, Jean Pascal ^l   Muracciole, Xavier ^m   Pichon, Marie France ⁿ   Bay, Jacques Olivier ^o   Elaidi, Reza ^p   Teghom, Corine ^p   Radvanyi, François ^q   Beuzeboc, Philippe ^r   more..

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Institut Cochin   (France)

^d FOCH HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f Clinique Victor Hugo   (France)

^g La Roche Sur Yon Hospital ^*  (France)

^h St Joseph Hospital   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k Clinique Hartman   (France)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m TIMONE HOSPITAL   (France)

ⁿ Center René Huguenin   (France)

^o Clinical Nutrition Department   (France)

^p ARTIC Group   (France)

^q CNRS   (France)

^r INSTITUT CURIE   (France)

more..

Author keywords

Advanced urothelial carcinoma; Gemcitabine; Her2 overexpression; Platinum salts; Trastuzumab

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; PLATINUM;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVANCED UROTHELIAL CARCINOMA; AGED; ALOPECIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; ILEUS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC UROTHELIAL CARCINOMA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; METABOLISM; MIDDLE AGED;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATINUM; RECEPTOR, ERBB-2;

EID: 84925424619     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.10.009     Document Type: Article

References (29)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W.W. Coebergh, and H. Comber Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403 Data available at http://eco.iarc.fr/eucan
2. H. von der Maase, L. Sengelov, J.T. Roberts, S. Ricci, L. Dogliotti, and T. Oliver Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
3. A. Dash, M.D. Galsky, A.J. Vickers, A.M. Serio, T.M. Koppie, and G. Dalbagni Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506 513
4. H. Linardou, G. Aravantinos, E. Efstathiou, C. Kalofonos, A. Anagnostopoulos, and C. Deliveliotis Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group Urology 64 2004 479 484
5. M.D. Galsky New developments in urothelial cancer Am Soc Clin Oncol Educ Book 32 2012 304 308
6. M.D. Galsky, G.J. Chen, W.K. Oh, J. Bellmunt, B.J. Roth, and R. Petrioli Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma Ann Oncol 23 2012 406 410
7. M. De Santis, J. Bellmunt, G. Mead, M. Kerst, M. Leahy, and P. Maroto Randomized phase II/III trial gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 J Clin Oncol 30 2012 191 199
8. P.D. Grivas, M. Day, and M. Hussain Urothelial carcinomas: a focus on human epidermal receptors signaling Am J Transl Res 3 2011 362 373
9. M. Yan, B.A. Parker, R. Schwab, and R. Kurzrock HER2 aberrations in cancer: implications for therapy Cancer Treat Rev 40 2014 770 780
10. M. Peyromaure, F. Scotte, D. Amsellem-Ouazana, A. Vieillefond, S. Oudard, and P. Beuzeboc Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients Eur Urol 48 2005 771 775 Discussion 775-778
11. M. Salzberg, M. Borner, J.A. Bauer, R. Morant, D. Rauch, and C. Rochlitz Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients Eur J Cancer 42 2006 2660 2661
12. M.H. Hussain, G.R. MacVicar, D.P. Petrylak, R.L. Dunn, U. Vaishampayan, and P.N. Lara Jr. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial J Clin Oncol 25 2007 2218 2224
13. C. Wülfing, J.P. Machiels, D.J. Richel, M.O. Grimm, U. Treiber, and M.R. De Groot A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma Cancer 115 2009 2881 2890
14. A.C. Wolff, M.E. Hammond, D.G. Hicks, M. Dowsett, L.M. McShane, and K.H. Allison American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 31 2013 3997 4013
15. M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients Ann Oncol 21 2010 815 819
16. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
17. J.M. Lachin, and M.A. Foulkes Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification Biometrics 42 1986 507 519
18. Z. Latif, A.D. Watters, I. Dunn, K.M. Grigor, M.A. Underwood, and J.M. Bartlett HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder Br J Cancer 89 2003 1305 1309
19. C.L. Coogan, C.R. Estrada, S. Kapur, and K.J. Bloom HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder Urology 63 2004 786 790
20. G. Sauter, H. Moch, D. Moore, P. Carroll, R. Kerschmann, and K. Chew Heterogeneity of erbB-2 gene amplification in bladder cancer Cancer Res 53 1993 2199 2203
21. C.B. Ching, M.B. Amin, R.R. Tubbs, P. Elson, E. Platt, and R. Dreicer HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization Mod Pathol 24 2011 1111 1119
22. S.A. Schneider, W.R. Sukov, I. Frank, S.A. Boorjian, B.A. Costello, and R.F. Tarrell Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome Mod Pathol 27 2014 758 764
23. F. Liedberg, H. Anderson, G. Chebil, S. Gudjonsson, M. Höglund, and D. Lindgren Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 26 2008 17 24
24. P.H. Rajjayabun, P.E. Keegan, J. Lunec, and J.K. Mellon ErbB receptor expression patterns in human bladder cancer Urology 66 2005 196 200
25. S. Krüger, G. Weitsch, H. Büttner, A. Matthiensen, T. Böhmer, and T. Marquardt Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome Int J Oncol 21 2002 981 987
26. C. Bolenz, S.F. Shariat, P.I. Karakiewicz, R. Ashfaq, R. Ho, and A.I. Sagalowsky Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder BJU Int 106 2010 1216 1222
27. L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, and F. Ettore Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification Clin Cancer Res 13 2007 6404 6409
28. S. Girish, M. Gupta, B. Wang, D. Lu, I.E. Krop, and C.L. Vogel Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemother Pharmacol 69 2012 1229 1240
29. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322